Umbilical cord cells as a source of cardiovascular tissue engineering

被引:0
作者
Breymann, Christian [1 ,2 ]
Schmidt, Doerthe [3 ,4 ]
Hoerstrup, S. P. [3 ,4 ]
机构
[1] Univ Zurich Hosp, Feto Maternal Haematol Unit, Feto Maternal Haematol Res Grp, CH-8091 Zurich, Switzerland
[2] Seefeld Hirslanden Clin, Obstet & Gynaecol Ctr, GGS, Zurich, Switzerland
[3] Univ Zurich Hosp, Dept Surg Res, CH-8091 Zurich, Switzerland
[4] Univ Zurich Hosp, Cardiovasc Surg Clin, CH-8091 Zurich, Switzerland
来源
STEM CELL REVIEWS | 2006年 / 2卷 / 02期
关键词
human umbilical cord; stem cells; tissue engineering; cardiovascular; heart defect; congenital;
D O I
暂无
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
There is increasing scientific evidence that human umbilical cord cells are a valuable source of adult stem cells that can be used for various implications including regenerative medicine and tissue engineering. The review describes the role of progenitor cells (mesenchymal, endothelial, prenatal) for the use in cardiovascular tissue engineering, i.e., the formation of large vessels and heart valves from umbilical cord cells. Currently used replacements in cardiovascular surgery are made of foreign materials with well known drawbacks such as thrombo-embolic complications, infection, loss of functional and biological properties, and others. Especially in the field of replacements in congenital cardiac defects, there would be a need of materials which have the advantage of optimal biological and mechanical properties. In the case of human umbilical cord cells, autologous cells can be used by minimally invasive procedures. The cells have excellent growth capacities and form a neo-matrix with excellent mechanical properties. For optimal growth and modeling, scaffolds are required with high biocompatibility and biodegradability, which allow cell attachment, ingrowth, and organization. Nutrients and waste must be easily transported and cells should be in entire contact with host's body. Finally, regenerated materials can be fully incorporated and the scaffold is completely replaced. Besides these cell and scaffold requirements, feto-maternal conditions and risk factors concerning deriving stem cells are of major interest. There are still many open questions concerning whether and how maternal conditions such as infection ( viral or bacterial) or gestational age of the newborn influence stem cell harvesting and quality. If these cells will be used for the construction of replacement materials, it is clear that very strict criteria and protocols be introduced enabling the promising step from isolated cells to a therapeutic device such as a new heart valve. It is hoped that it will be only a question of time until human umbilical cord cells will be used frequently as the source of cardiovascular
引用
收藏
页码:87 / 92
页数:6
相关论文
共 17 条
[1]   Amniotic fluid and placental stem cells [J].
Fauza, D .
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2004, 18 (06) :877-891
[2]   Living, autologous pulmonary artery conduits tissue engineered from human umbilical cord cells [J].
Hoerstrup, SP ;
Kadner, A ;
Breymann, C ;
Maurus, CF ;
Guenter, CI ;
Sodian, R ;
Visjager, JF ;
Zund, G ;
Turina, MI .
ANNALS OF THORACIC SURGERY, 2002, 74 (01) :46-52
[3]   New pulsatile bioreactor for in vitro formation of tissue engineered heart valves [J].
Hoerstrup, SP ;
Sodian, R ;
Sperling, JS ;
Vacanti, JP ;
Mayer, JE .
TISSUE ENGINEERING, 2000, 6 (01) :75-79
[4]   Human umbilical cord cells for cardiovascular tissue engineering: a comparative study [J].
Kadner, A ;
Zund, G ;
Maurus, C ;
Breymann, C ;
Yakarisik, S ;
Kadner, G ;
Turina, M ;
Hoerstrup, SP .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2004, 25 (04) :635-641
[5]  
Kadner A, 2002, ANN THORAC SURG, V74, pS1422
[6]   Umbilical cord blood-derived cells for tissue repair [J].
Körbling, M ;
Robinson, S ;
Estrov, Z ;
Champlin, R ;
Shpall, E .
CYTOTHERAPY, 2005, 7 (03) :258-261
[7]  
MAYER J, 1995, SEM THORAC CARDIOVAS, V7
[8]  
SANATLOYA J, 2005, J SOC GYNECOL INVEST, V12, pA237
[9]   Living patches engineered from human umbilical cord derived fibroblasts and endothelial progenitor cells [J].
Schmidt, D ;
Mol, A ;
Neuenschwander, S ;
Breymann, C ;
Gössi, M ;
Zund, G ;
Turina, M ;
Hoerstrup, SP .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2005, 27 (05) :795-799
[10]   Umbilical cord blood derived endothelial progenitor cells for tissue engineering of vascular grafts [J].
Schmidt, D ;
Breymann, C ;
Weber, A ;
Guenter, CI ;
Neuenschwander, S ;
Zund, G ;
Turina, M ;
Hoerstrup, SP .
ANNALS OF THORACIC SURGERY, 2004, 78 (06) :2094-2098